(600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600867 · · 15 pages · Chinese
Summary by 6ix AI
The report highlights significant decreases in total profit and net profit attributable to shareholders compared to the same period last year. Despite these declines, the company reported an increase in operating revenue for the current quarter. The financial statements included in the report have not been audited.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Tonghua Dongbao Pharmaceutical Co., Ltd. on 6ix
Earlier from Tonghua Dongbao Pharmaceutical
- (600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Completion of the Non-trading Transfer of Shares for the Reserved Portion under the R&D and Production System Employee Stock Ownership Plan
- (600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Completion of the Non-trading Transfer of Shares for the Reserved Portion under the 2025 Employee Stock Ownership Plan
- Announcement on Satisfaction of Unlocking Conditions for the First Lock-up Period of the Initial Grant under the 2025 Employee Stock Ownership Plan and Expiration of the Lock-up Period
- (600867)"Tonghua Dongbao Pharmaceutical Co., Ltd."Announcement on Pledge Release and Re-pledge of Shares Held by the Controlling Shareholder
- Announcement on Allocation of Reserved Portion under Employee Stock Ownership Plan for R&D and Production System
Follow Tonghua Dongbao Pharmaceutical into a list and get an email when it puts out news.
Follow Tonghua Dongbao Pharmaceutical